The U.S. Food and Drug Administration has approved a nasal spray developed by Pfizer as a means to quickly treat the painful symptoms associated with suffering a migraine.
The drug, Zavzpret, also known as zavegepant, was approved on Thursday for the treatment of acute migraines with or without an aura in adults. It’s expected to launch in July, Reuters reported.
“The FDA approval of Zavzpret marks a significant breakthrough for people with migraine who need freedom from pain and prefer alternative options to oral medications,” said Pfizer’s Angela Hwang, Chief Commercial Officer, President, Global Biopharmaceuticals Business.
